297 related articles for article (PubMed ID: 15970124)
21. Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Bassand JP
Haemostasis; 2000; 30 Suppl 2():114-21; discussion 106-7. PubMed ID: 11251354
[TBL] [Abstract][Full Text] [Related]
22. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
[TBL] [Abstract][Full Text] [Related]
23. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Popma JJ; Berger P; Ohman EM; Harrington RA; Grines C; Weitz JI
Chest; 2004 Sep; 126(3 Suppl):576S-599S. PubMed ID: 15383485
[TBL] [Abstract][Full Text] [Related]
24. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
25. Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease.
Verheugt FW
Haemostasis; 2000; 30 Suppl 2():122-7; discussion 106-7. PubMed ID: 11251355
[TBL] [Abstract][Full Text] [Related]
26. [Clopidogrel should be added to aspirin for at least 1 year after percutaneous coronary interventions (CREDO) while before them its loading dose can reach 600mg (ISAR-COOL)].
Gratsianskiĭ NA
Kardiologiia; 2003; 43(5):71-3. PubMed ID: 12942928
[No Abstract] [Full Text] [Related]
27. Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry.
Seth A; Sinha N; Parikh K; Patel T; Hiremath MS; Mehta AB; Chandra P; Pinto B; Sethi KK; Sengottuvelu S
Indian Heart J; 2008; 60(4):333-41. PubMed ID: 19242012
[TBL] [Abstract][Full Text] [Related]
28. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
29. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Kwa AT; Rogers JH
J Interv Cardiol; 2008 Apr; 21(2):107-17. PubMed ID: 18248357
[TBL] [Abstract][Full Text] [Related]
30. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
32. Bivalirudin: an anticoagulant option for percutaneous coronary intervention.
Bates ER
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):153-62. PubMed ID: 15151464
[TBL] [Abstract][Full Text] [Related]
33. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
35. Antithrombotic agents: implications in dentistry.
Little JW; Miller CS; Henry RG; McIntosh BA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 May; 93(5):544-51. PubMed ID: 12075203
[TBL] [Abstract][Full Text] [Related]
36. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
37. [Antithrombotic therapy during percutaneous coronary interventions].
Verheugt FW; Dieker H; Aengevaeren WR
Ned Tijdschr Geneeskd; 2005 Apr; 149(17):912-6. PubMed ID: 15884403
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
Jennings LK; Saucedo JF
Curr Opin Cardiol; 2008 Jul; 23(4):302-8. PubMed ID: 18520712
[TBL] [Abstract][Full Text] [Related]
39. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
[TBL] [Abstract][Full Text] [Related]
40. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
